Corrigendum

Nature 444, 512 (23 November 2006) | doi:10.1038/nature05423

Potential of stem-cell-based therapies for heart disease

Deepak Srivastava and Kathryn N. Ivey

Nature 441, 1097–1099 (2006)

It has been drawn to our attention (by J. Lakota, and by J. J. Minguell and G. P. Lasala) that we used the abbreviation for bone-marrow-derived stem cells (BMSCs) inappropriately in some parts of our Insight Progress article. BMSC is a commonly used acronym for the heterogeneous adult stem cells in bone marrow. The term BMSC was used with this intention, but was placed after describing a study on bone-marrow-derived mesenchymal stem cells, which are a subset of BMSCs. Subsequent references to BMSCs were intended to describe the heterogeneous cells, rather than the specific mesenchymal subtype. Most clinical trials for myocardial infarction used BMSCs and have so far had mixed results. Future trials with isolated mesenchymal stem cells will reveal their potential in the context of heart disease.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Stem cells REGENT trial?the end of cell therapy for MI?

Nature Reviews Cardiology News and Views (01 Sep 2009)

Helping the heart to heal with stem cells

Nature Medicine News and Views (01 Apr 2001)

See all 3 matches for News And Views

Extra navigation

.

naturejobs

ADVERTISEMENT